Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Association of cigarette smoking with HIV prognosis among women in the HAART era: a report from the women's interagency HIV study.

Feldman JG, Minkoff H, Schneider MF, Gange SJ, Cohen M, Watts DH, Gandhi M, Mocharnuk RS, Anastos K.

Am J Public Health. 2006 Jun;96(6):1060-5. Epub 2006 May 2.

2.

CYP1A1 genotype modifies the impact of smoking on effectiveness of HAART among women.

Feldman DN, Feldman JG, Greenblatt R, Anastos K, Pearce L, Cohen M, Gange S, Leanza S, Burk R.

AIDS Educ Prev. 2009 Jun;21(3 Suppl):81-93. doi: 10.1521/aeap.2009.21.3_supp.81.

3.

Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy.

Tai JH, Udoji MA, Barkanic G, Byrne DW, Rebeiro PF, Byram BR, Kheshti A, Carter JD, Graves CR, Raffanti SP, Sterling TR.

J Infect Dis. 2007 Oct 1;196(7):1044-52. Epub 2007 Aug 29.

4.

The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy.

Anastos K, Barrón Y, Cohen MH, Greenblatt RM, Minkoff H, Levine A, Young M, Gange SJ.

Ann Intern Med. 2004 Feb 17;140(4):256-64.

PMID:
14970148
5.

Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa.

Reddi A, Leeper SC, Grobler AC, Geddes R, France KH, Dorse GL, Vlok WJ, Mntambo M, Thomas M, Nixon K, Holst HL, Karim QA, Rollins NC, Coovadia HM, Giddy J.

BMC Pediatr. 2007 Mar 17;7:13.

6.

Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain).

Jaén A, Esteve A, Miró JM, Tural C, Montoliu A, Ferrer E, Riera M, Segura F, Force L, Sued O, Vilaró J, Garcia I, Masabeu A, Altès J, Coltet B, Podzamczer D, Murillas J, Navarro G, Gatell JM, Casabona J; PISCIS Study Group.

J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):212-20.

PMID:
18297762
7.

Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort.

Gutierrez F, Padilla S, Masiá M, Iribarren JA, Moreno S, Viciana P, Muñoz L, Gómez Sirvent JL, Vidal F, López-Aldeguer J, Blanco JR, Leal M, Rodríguez-Arenas MA, Perez Hoyos S; CoRIS-MD.

PLoS One. 2006 Dec 20;1:e89.

8.

Improved outcomes of HIV-1-infected adults with tuberculosis in the era of highly active antiretroviral therapy.

Hung CC, Chen MY, Hsiao CF, Hsieh SM, Sheng WH, Chang SC.

AIDS. 2003 Dec 5;17(18):2615-22.

PMID:
14685055
9.

The association of race, sociodemographic, and behavioral characteristics with response to highly active antiretroviral therapy in women.

Anastos K, Schneider MF, Gange SJ, Minkoff H, Greenblatt RM, Feldman J, Levine A, Delapenha R, Cohen M; Women's Interagency HIV Study Collaborative Group.

J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):537-44.

PMID:
16044004
10.

Clinical outcome of HIV-infected antiretroviral-naive patients with discordant immunologic and virologic responses to highly active antiretroviral therapy.

Tan R, Westfall AO, Willig JH, Mugavero MJ, Saag MS, Kaslow RA, Kempf MC.

J Acquir Immune Defic Syndr. 2008 Apr 15;47(5):553-8. doi: 10.1097/QAI.0b013e31816856c5.

PMID:
18285713
11.
12.

Are there gender differences in starting protease inhibitors, HAART, and disease progression despite equal access to care?

Mocroft A, Gill MJ, Davidson W, Phillips AN.

J Acquir Immune Defic Syndr. 2000 Aug 15;24(5):475-82.

PMID:
11035619
13.
14.

Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.

Srasuebkul P, Ungsedhapand C, Ruxrungtham K, Boyd MA, Phanuphak P, Cooper DA, Law MG.

HIV Med. 2007 Jan;8(1):46-54.

15.
16.

Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy.

Szczech LA, Hoover DR, Feldman JG, Cohen MH, Gange SJ, Goozé L, Rubin NR, Young MA, Cai X, Shi Q, Gao W, Anastos K.

Clin Infect Dis. 2004 Oct 15;39(8):1199-206. Epub 2004 Sep 27.

17.

Risk of progression to AIDS and death in women infected with HIV-1 initiating highly active antiretroviral treatment at different stages of disease.

Anastos K, Barrón Y, Miotti P, Weiser B, Young M, Hessol N, Greenblatt RM, Cohen M, Augenbraun M, Levine A, Muñoz A; Women's Interagency HIV Study Collaborative Study Group.

Arch Intern Med. 2002 Sep 23;162(17):1973-80.

PMID:
12230420
18.

Response to highly active antiretroviral therapy according to duration of HIV infection.

Pezzotti P, Pappagallo M, Phillips AN, Boros S, Valdarchi C, Sinicco A, Zaccarelli M, Rezza G; Italian Seroconversion Study.

J Acquir Immune Defic Syndr. 2001 Apr 15;26(5):473-9.

PMID:
11391168
19.

Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users.

Wood E, Montaner JS, Yip B, Tyndall MW, Schechter MT, O'Shaughnessy MV, Hogg RS.

CMAJ. 2003 Sep 30;169(7):656-61.

20.

Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART.

Hogg RS, Bangsberg DR, Lima VD, Alexander C, Bonner S, Yip B, Wood E, Dong WW, Montaner JS, Harrigan PR.

PLoS Med. 2006 Sep;3(9):e356.

Items per page

Supplemental Content

Write to the Help Desk